Pau Montesinos

Spain

Research Interests

Explore related searches

Professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (7)

Jan Novak

CZECH REPUBLIC

View details

Stephane De Botton

FRANCE

View details

Tadeusz Robak

Professor

Medical University of Lodz

POLAND

View details

Hans Beier Ommen

DENMARK

View details

Hee-Je Kim

Professor

SOUTH KOREA

View details

Richard Larson

Professor

University of Chicago

UNITED STATES

View details

Paresh Vyas

University of Oxford

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Pau Montesinos

Research Interests

Explore related searches

Contact this professor

Articles (10)

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial

Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial

Identifying prognostic gene panels in acute myeloid leukemia

Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain

Midostaurin plus daunorubicin or idarubicin for young and elderly adults with FLT3-mutated AML: a Phase 3b trial

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML

A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia

Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape

Revisiting coexisting chromosomal abnormalities in NPM1-mutated AML in light of the revised ELN 2022 classification

Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy

Collaborators (7)

Jan Novak

Stephane De Botton

Tadeusz Robak

Hans Beier Ommen

Hee-Je Kim

Richard Larson

Paresh Vyas

Make your next move.